Abstract | BACKGROUND: OBJECTIVE: METHODS: Here, we summarize the basics for the establishment of the in vitro and in vivo conditions for the generation of TH2 immune responses, followed by various experimental data showing the therapeutic use of IL-4 for the therapy of autoimmune diseases. This data and early experiences with recombinant human IL-4 (rhIL-4) in the therapy of patients with cancer set the basis for the clinical introduction of rhIL-4 in the treatment of patients with psoriasis in a Phase I/II trial. CONCLUSION:
IL-4 seems to act by inducing an anti-inflammatory phenotype and further clinical trials will explore the promising therapeutic potency of IL-4 in psoriasis during the upcoming era of biologics.
|
Authors | Christina Weigert, Martin Röcken, Kamran Ghoreschi |
Journal | Expert opinion on drug discovery
(Expert Opin Drug Discov)
Vol. 3
Issue 3
Pg. 357-68
(Mar 2008)
ISSN: 1746-0441 [Print] England |
PMID | 23480267
(Publication Type: Journal Article)
|